Drug Profile


Alternative Names: TH-070

Latest Information Update: 04 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Threshold Pharmaceuticals
  • Class Cytostatics; Indazoles; Small molecules
  • Mechanism of Action Glycolysis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Sep 2006 Interim results from discontinued phase II and phase III clinical trials in patients with benign prostatic hyperplasia have been added to the adverse events and Mens Health therapeutic trials sections
  • 17 Jul 2006 Discontinued - Phase-II for Benign prostatic hyperplasia in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top